Document:

f8k120409ex10viii_naturlnano.htm

     

     

    Exhibit
10.8

     

    
      NaturalNano,
Inc.

      NaturalNano
Research, Inc.

      15 Schoen
Place

      Pittsford,
New York 14534-2025

       

      November
30, 2009

      

      Platinum
Long Term Growth IV, LLC

      152 West
57th
Street, 54th
Floor

      New York,
New York 10019

      

      Platinum
Advisors LLC

      152 West
57th
Street, 54th
Floor

      New York,
New York 10019

      

      Longview
Special Finance Inc.

      Trident
Chambers

      P.O.Box
146

      Road
Town, Tortola,

      British
Virgin Islands

      

      Ladies
and Gentlemen:

      

      NaturalNano,
Inc. (the “Company”) is requesting the Senior Creditors’ consent to the issuance
by the Company of a subordinate convertible promissory note in the aggregate
principal amount of $225,000 (the “Junior Note”), convertible (subject to
adjustment) at a conversion price of $.005 per share of Common Stock of the
Company.  The Junior Note, and any agreements entered into in connection
with the Note, shall provide that the Note shall be expressly subordinate, in
right of payment and security, to all indebtedness of the Company (the “Senior
Debt”) to Platinum Long Term Growth IV, LLC, Longview Special Finance Inc. and
Platinum Advisors LLC (collectively, the “Senior Creditors”).  In
connection with the issuance of the Junior Note, the Company is also issuing a
Common Stock Purchase Warrant (the “Warrant”) to purchase 45,000,000 shares of
the Company’s Common Stock at an initial exercise price of $.025 per share
(subject to adjustment).

      

      The
Company covenants and agrees with the Senior Creditors that (i) it will not
make, and will not permit any subsidiary to make, directly or indirectly, any
payment in respect of the Junior Note or the Warrant (other than conversion or
exercise of the same into Common Stock of the Company), whether in respect of
principal, interest, redemption price or otherwise, until payment in full of the
Senior Debt, whether or not the Senior Debt is then due and payable, or whether
or not the Senior Creditors have agreed to forbear their remedies in respect
thereof, (ii) the Junior Note shall provide that it is subordinate to the Senior
Debt with respect to payment and security and (iii) any agreement purporting to
grant to the holders of the Junior Note any lien on assets of the Company shall
provide that the exercise of remedies with respect to such assets shall provide
for the prior payment in full of all Senior Debt.  It is further agreed to
by the Company that any default or event of default pursuant to the Junior Note
shall be deemed to 

       

       

      
        
          
          

        

        
          
          

          
            

          

        

        
          
          

        

      

       

       

      constitute
a default or Event of Default under the Senior Debt and shall automatically
terminate any forbearance of the Senior Creditors’ rights to enforce the
provisions of the Senior Debt and related agreements.  In no event shall
any consent hereunder be deemed to waive any conversion price or exercise price
adjustment that may triggered upon the issuance, exercise or conversion of the
Junior Note and the Warrant under any warrants or convertible securities held by
the Senior Creditors, including the Senior Debt and the warrant issued in
connection therewith.

       

       

      
        	
                 Very truly
      yours, 

                 

                 NATURALNANO, INC.

                 

              	 
	 	 	 
	 By:	   /s/ James Wemett	 
	 	 Name: 	 James
    Wemett	 
	 	 Title:	 Acting CEO	 

      

      

       

       

                                                      

      
        Accepted
and agreed to this

        30th day
of November, 2009 by:

        

        PLATINUM
LONG TERM GROWTH IV, LLC

         

         

        
          	 By:	   /s/ Mark
      Nordlicht                            
	 	 Name: 	 Mark
      Nordlicht 
	 	 Title:	 G.M.

        

         

        

        PLATINUM
ADVISORS LLC

         

         

        
          	 By:	   /s/ Mark
      Nordlicht                            
	 	 Name: 	 Mark
    Nordlicht
	 	 Title:	 G.M.

        
        

        LONGVIEW
SPECIAL FINANCE INC.

        

         

        
          	 By:	   /s/ Francois         
            [illegible]
	 	 Name: 	 Francois
             
           [illegible]
	 	 Title:	 Directorex101.htm

Exhibit 10.1

 

ONCOTHYREON INC.

 

AMENDMENT TO ROBERT KIRKMAN OFFER LETTER

 

This amendment (the “Amendment”) is made by and between Robert Kirkman (“Executive”) and Oncothyreon Inc., a Delaware corporation (the “Company”
and together with the Executive hereinafter collectively referred to as the “Parties”) on December 3, 2009.

 

WITNESSETH:

 

WHEREAS, the Parties previously entered into an offer letter, dated August 29, 2006, as amended on December 31, 2008 (the “Offer Letter”); and

 

WHEREAS, the Company and Executive desire to amend certain provisions of the Offer Letter in order to provide Executive with certain Change in Control benefits;

 

NOW, THEREFORE, for good and valuable consideration, Executive and the Company agree that the Offer Letter is hereby amended as follows:

 

1.           Severance.  Section 5 of the Offer Letter is hereby amended and replaced in its entirety as follows:

 

“5.

 

Severance: In the event your employment is terminated for reasons other than “Cause” (as defined below) you will be entitled to the following:

 

i)           Lump sum payment of one year’s base salary, less required withholding,

 

ii)           Lump sum payment of one year’s equivalent of performance review bonus at target, less required withholding, and,

 

iii)           Stock options will follow the schedule detailed in item 4.

 

Such payments will be made within sixty (60) days following your termination of employment.

 

“Cause” for the purpose of this agreement shall include but not be limited to (i) willful engaging in illegal conduct or gross misconduct which is injurious to the Company or an affiliated company, (ii) being convicted of, or entering a plea of nolo contendere or
guilty to, a felony or a crime of moral turpitude; (iii) engaging in fraud, misappropriation, embezzlement or any other act or acts of dishonesty resulting or intended to result directly or indirectly in a gain or personal enrichment to you at the expense of the Company or an affiliated company, (iv) material breach of any written policies of the Company or an affiliated company, or (v) willful and continual failure substantially to perform your duties with the Company, which failure has continued for a period
of at least 30 days after written notice by the Company.

 

 

 

 

 

Section 409A.

 

i)           Notwithstanding anything to the contrary in this letter agreement, no severance payable to you, if any, pursuant to this letter agreement that, when considered together with any other severance payments or separation benefits, are considered deferred compensation under
Section 409A (together, the “Deferred Payments”) will be payable until you have a “separation from service” within the meaning of Section 409A. Similarly, no severance payable to you, if any, pursuant to this letter agreement that otherwise would be exempt from Section 409A pursuant to Treasury Regulation Section 1.409A-1(b)(9) will be payable until you have a “separation from service” within the meaning
of Section 409A.

 

ii)           Notwithstanding anything to the contrary in this letter agreement, if you are a “specified employee” within the meaning of Section 409A at the time of your separation from service, then, if required, the Deferred Payments, which are otherwise due to you
on or within the six (6) month period following your separation from service will accrue, to the extent required, during such six (6) month period and will become payable in a lump sum payment on the date six (6) months and one (1) day following the date of your separation from service or the date of your death, if earlier. All subsequent Deferred Payments, if any, will be payable in accordance with the payment schedule applicable to each payment or benefit. Each payment and benefit payable under this letter
agreement is intended to constitute a separate payment for purposes of Treasury Regulation Section 1.409A-2(b)(2).

 

iii)           Any amount paid under the letter agreement that satisfies the requirements of the “short-term deferral” rule set forth in Section 1.409A-1(b)(4) of the Treasury Regulations will not constitute Deferred Payments for purposes of clause (i) above.

 

iv)           Any amount paid under this letter agreement that qualifies as a payment made as a result of an involuntary separation from service pursuant to Section 1.409A-1(b)(9)(iii) of the Treasury Regulations that does not exceed the Section 409A Limit will not constitute Deferred
Payments for purposes of clause (i) above. “Section 409A Limit” will mean the lesser of two (2) times: (i) your annualized compensation based upon the annual rate of pay paid to you during your taxable year preceding your taxable year of your termination of employment as determined under Treasury Regulation Section 1.409A-1(b)(9)(iii)(A)(1) and any Internal Revenue Service guidance issued with respect thereto; or (ii) the maximum amount that may be taken into account under a qualified plan pursuant
to Section 401(a)(17) of the Internal Revenue Code for the year in which your employment is terminated.

 

v)           The foregoing provisions are intended to comply with the requirements of Section 409A so that none of the severance payments and benefits to be provided hereunder will be subject to the additional tax imposed under Section 409A, and any ambiguities herein will be interpreted
to so comply. You and the Company agree to work together in good faith to consider amendments to this letter agreement and to take such reasonable actions which are necessary, appropriate or desirable to avoid imposition of any additional tax or income recognition prior to actual payment to you under Section 409A.”

 

 

 

 

 

2.           Change in Control.  Section 17 of the Offer Letter is hereby added as follows:

 

“17.

 

Change in Control: In the event there is a “Change in Control” as defined herein and you remain employed through the date of the Change in Control, you will be entitled to the following:

 

i)           Lump sum payment of two year’s base salary, less required withholding, and

 

ii)           Lump sum payment of two year’s equivalent of performance review bonus at target, less required withholding.

 

Such payments will be made within sixty (60) days following the consummation of the Change in Control, provided that, within forty-five (45) days of the Change in Control, you have signed a separation agreement in a form reasonably satisfactory to the Company, which shall include a general release of all claims against the Company
and its affiliated entities.

 

“Change in Control” for the purpose of this agreement shall be deemed to have occurred if, on or after the date hereof (i) the board of directors of the Company passes a resolution to the effect that, for purposes of the Company’s Amended and Restated Share Option Plan, a Change in Control has occurred or (ii) any
person or any group of two or more persons acting jointly or in concert becomes the beneficial owner, directly or indirectly, or acquires the right to control or direct, twenty-five (25%) percent or more of the outstanding voting securities of the Company or any successor to the Company in any manner, including without limitation as a result of a takeover bid or an amalgamation of the Company with any other corporation or any other business combination or reorganization, and for purposes hereof “voting
security” means any security other than a debt security carrying a voting right either under all circumstances or under some circumstances that have occurred and are continuing.”

 

3.           Full Force and Effect.  To the extent not expressly amended hereby, the Offer Letter shall remain in full force and effect.

 

4.           Entire Agreement.  This Amendment and the Offer Letter constitute the full and entire understanding and agreement between the Parties with regard to the subjects hereof and thereof.  This
Amendment may be amended at any time only by mutual written agreement of the Parties.

 

5.           Counterparts.  This Amendment may be executed in counterparts, all of which together shall constitute one instrument, and each of which may be executed by less than all of the parties to this
Amendment.

 

6.           Governing Law.  This Amendment will be governed by the laws of the State of Washington (with the exception of its conflict of laws provisions).

 

 

 

 

 

IN WITNESS WHEREOF, each of the Parties has executed this Amendment, in the case of the Company by its duly authorized officer, as of the date set forth above.

 

	COMPANY       	ONCOTHYREON INC.	 
	 	 	 	 
	
 
	 /s/ Gary Christianson    	 
	 	By: 	Gary Christianson	 
	 	Title: 	Chief Operating Officer 	 
	 	 	 	 
	EXECUTIVE 	ROBERT KIRKMAN, M.D.	 
	 	 	 	 
	 	/s/ Robert Kirkman, M.D.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00166-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00166-of-00352.parquet"}]]